Once-daily OROS® methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder
Once-daily OROS® methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder
复制标题
DOI：
10.1089/cap.2006.16.351
复制
发表时间：
2006-06-01
影响因子：
1.9
通讯作者：
Stein, Mark
中科院分区：
文献类型：
--
作者：
McGough, James J.;McBurnett, Keith;Stein, Mark
这项为期 8 周、开放标签的双盲研究扩展报告了 171 名患有注意力缺陷/多动障碍 (ADHD) 的青少年的安全性数据，这些青少年每天接受一次 OROS (R) 哌醋甲酯 (MPH)（18-72 毫克/天）。头痛、厌食和失眠是最常报告的治疗相关不良事件。不良事件的发生率与剂量无关。 OROS MPH 在剂量高达 72 毫克/天时是安全的且耐受性良好。
This 8-week, open-label extension of a double-blind study reports on safety data for 171 adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily OROS (R) methylphenidate (MPH) (18-72 mg/day). Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day.